ADAlp Dogu

Alp Dogu

*This is an algorithmically generated author record based on publicly available information.

Alp Dogu has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mass Gatherings as Amplifiers of Meningococcal Disease: A Modeling Study of Hajj and Umrah

    by Laurent Coudeville, Musallam Abuhasan, Abrar Alasmari, Anas Khan, Saber Yezli, Refaat Abdelaziz, Florence Coste, Alp Dogu, Angie Upegui, George Wahba, et al.

  • Open Access

    Immunogenicity and Safety of Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Potential Hajj/Umrah Pilgrims Aged ≥ 56 Years: A Phase III, Open-Label Study

    by Ghassan S. Dbaibo, Ismail Balik, İrEm Akdemir, Turan Buzgan, Rahmet Guner, Celina F. Boutros, Stephanie Damaj, Zeinab El Zein, Sarah Merhi, Kawthar Faour, et al.

    Introduction Invasive meningococcal disease poses a substantial disease burden worldwide, including older adults (aged ≥ 56 years) along with higher case fatality rates. MenACYW-TT, a quadrivalent meningococcal tetanus toxoid-conjugate vaccine, is indicated worldwide in individuals ≥ 56 years of age and is the only licensed vaccine in the USA for this age group. The annual Hajj pilgrimage is considered an epidemiologic event with approximately two million pilgrims per year; hence, immunization with a quadrivalent meningococcal vaccine is mandatory for visitors traveling to Saudi Arabia for Umrah and Hajj. We evaluated the immunogenicity and safety of a single dose of MenACYW-TT in prospective Hajj/Umrah pilgrims aged ≥ 56 years in Turkiye and Lebanon. Methods In this open-label phase III study (NCT03869866), conducted in Turkiye and Lebanon, healthy adults aged ≥ 56 years received a single dose of the MenACYW-TT vaccine. Serum bactericidal assays were performed using human (hSBA) and rabbit (rSBA) complements to measure antibody titers against all four serogroups at baseline (D0) and 30 days post vaccination (D30). Safety data were collected up to 30 days (+ 14 days) post vaccination. Results A total of 290 individuals were enrolled in the study. On D30, vaccine seroprotection rates (hSBA titers ≥ 1:8) for serogroups A, C, Y, and W were 82.8%, 92.5%, 92.1%, and 83.5%, respectively, and rSBA titers (≥ 1:128) were 83.4%, 90.0%, 94.3%, and 88.9%, respectively. hSBA geometric mean titers (GMTs) were 32 [95% confidence interval (CI) 26.3–39.1], 132 (102–169), 126 (99.3–161), and 56.4 (43.8–72.6) for serogroups A, C, Y, and W, respectively. On D30, seroresponse rates in the per-protocol analysis set (PPAS) were 48–71.0%. Safety concerns and any serious adverse events related to the study vaccine were not observed. Conclusions MenACYW-TT vaccine induced a robust immune response against all serogroups (per seroprotection rates and GMTs). A single dose of the vaccine demonstrated acceptable safety profile in potential pilgrims aged ≥ 56 years. Trial Registration ClinicalTrials.gov, NCT03869866. A Graphical Abstract is available for this article. Graphical Abstract


  • Open Access

    The epidemiology of meningococcal meningitis: multicenter, hospital-based surveillance of meningococcal meningitis in Iraq

    by Tarek Al-Sanouri, Sabah Mahdi, Ilham Abu Khader, Asaad Mahdi, Alp Dogu, Amine Amiche, Sereen Iweir, Mudhafar Qader, Adel Belbaisi, Riyad AlHilfi


  • Open Access

    Systematic review of invasive meningococcal disease epidemiology in the Eastern Mediterranean and North Africa region

    by Alp Giray Dogu, Anouk M. Oordt-Speets, Femke van Kessel-De Bruijn, Mehmet Ceyhan, Amine Amiche

    Background: Invasive meningococcal disease (IMD) represents a global health burden. However, its epidemiology in the Eastern Mediterranean (EM) and North Africa (NA) regions is currently not well understood. This review had four key objectives: to describe asymptomatic meningococcal carriage, IMD epidemiology (e.g. serogroup prevalence, case-fatality rates [CFRs]), IMD presentation and management (e.g. clinical diagnosis, antibiotic treatments) and economic impact and evaluation (including health technology assessment [HTA] recommendations) in EM and NA.Methods: A systematic literature search (MEDLINE and EMBASE) was conducted (January 2000 to February 2021). Search strings included meningococcal disease and the regions/countries of interest. Identified publications were screened sequentially by title/abstract, followed by screening of the full-text article; articles were also assessed on methodological quality. Literature reviews, genetic sequencing or diagnostic accuracy studies, or other non-pertinent publication type were excluded. An additional grey literature search (non-peer-reviewed sources; start date January 2000) was conducted to the end of April 2019.Results: Of the 1745 publications identified, 79 were eligible for the final analysis (n = 61 for EM and n = 19 for NA; one study was relevant to both). Asymptomatic meningococcal carriage rates were 0–33% in risk groups (e.g. military personnel, pilgrims) in EM (no data in NA). In terms of epidemiology, serogroups A, B and W were most prevalent in EM compared with serogroups B and C in NA. IMD incidence was 0–20.5/100,000 in EM and 0.1–3.75/100,000 in NA (reported by 7/15 countries in EM and 3/5 countries in NA). CFRs were heterogenous across the EM, ranging from 0 to 57.9%, but were generally lower than 50%. Limited NA data showed a CFR of 0–50%. Data were also limited in terms of IMD presentation and management, particularly relating to clinical diagnosis/antibiotic treatment. No economic evaluation or HTA studies were found.Conclusions: High-risk groups remain a significant reservoir of asymptomatic meningococcal carriage. It is probable that inadequacies in national surveillance systems have contributed to the gaps identified. There is consequently a pressing need to improve national surveillance systems in order to estimate the true burden of IMD and guide appropriate prevention and control programmes in these regions.